Navigation Links
Ohio State study: Targeted ovarian cancer therapy not cost-effective
Date:3/7/2011

COLUMBUS, Ohio An analysis conducted by Ohio State University cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective.

The findings comparing the relative value of various clinical strategies will be published online March 7 in the Journal of Clinical Oncology.

The researchers performed a cost-effectiveness analysis looking at a clinical trial conducted by the Gynecologic Oncology Group (GOG) studying the use of bevacizumab along with standard chemotherapy for patients with advanced ovarian cancer, said first author Dr. David E. Cohn, a gynecologic surgical oncologist and researcher at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

Bevacizumab is a novel targeted therapy designed to inhibit angiogenesis, the process by which new blood vessels develop and carry vital nutrients to a tumor.

Although a discussion regarding cost-effectiveness of a potentially life-extending intervention invariably suggests the rationing of limited health care resources, the intent of this study was to provide a framework with which to evaluate the pending results of a clinical trial of three different interventions for ovarian cancer, said Cohn.

"We do not suggest that bevacizumab, also known by the brand name Avastin, should be withheld from a patient with ovarian cancer, but rather argue that studies evaluating the effectiveness of new treatments should also be interpreted with consideration of the expense," says Cohn, who collaborated with Dr. J. Michael Straughn Jr., an associate professor of obstetrics and gynecology at the University of Alabama at Birmingham.

The results of the randomized phase III GOG clinical trial demonstrated an additional 3.8 months of progression-free survival when maintenance bevacizumab was added for about one year following treatment with standard chemotherapy drugs carboplatin and paclitaxel along with bevacizumab.

"We put together a model looking at the variety of treatment arms on this clinical trial, each of which included 600 patients," said Cohn. "Given the fact that the addition of the drug was associated with 3.8 months of additional survival without cancer, we set out to determine whether or not that benefit of survival was justified by the expense of the drug."

The model showed that standard chemotherapy for patients in the clinical trial would cost $2.5 million, compared to $78.3 million for patients who were treated with standard chemotherapy and bevacizumab, plus additional maintenance treatments of bevacizumab for almost one year.

Bevacizumab has been used in the treatment of recurrent ovarian cancer, and the U.S. Food and Drug Administration has approved it for the treatment of colorectal, lung, breast, brain (glioblastoma) and renal cell cancers.

Typically each treatment with bevacizumab costs $5,000, with most of those costs directly attributable to the cost of the drug, Cohn said.

Effectiveness was defined as months of progression-free survival, and costs were calculated as total costs per strategy. Cost-effectiveness strategies were defined as the cost per year of progression-free survival. Incremental cost-effectiveness ratio was defined as the costs per progression-free life-year saved.

"Ultimately, we found that if you reduced the drug cost to 25 percent of the baseline, it does become cost effective to treat patients with bevacizumab," said Cohn. "Or, if the survival could be substantially increased above the 3.8 months of progression-free survival, that could lead to cost-effective treatment for patients with advanced ovarian cancer."

Ovarian cancer is the most lethal gynecologic cancer, with almost 14,000 women expected to die from the disease this year, according to the American Cancer Society.

"It is anticipated that in the future, there will be increased scrutiny regarding the individual and societal costs of an effective medication," said Cohn. "We hope that future clinical trials will incorporate the prospective collection of cost, toxicity and quality-of-life data to allow for a fully informed interpretation of the results."


'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. ACP applauds President Obamas call for state innovation on health insurance coverage
2. K-State chemists work brings more national recognition as promising early-career scientist
3. Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study
4. Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
5. PSA velocity screening for prostate cancer may lead to unnecessary biopsies
6. Change in PSA level does not predict prostate cancer
7. PSA Screening for Prostate Cancer Dips in Large U.S. Health Network
8. Wayne State University researchers publish results settling multiple sclerosis debate
9. Innovative International Healthcare Partnership established at Arizona State University
10. HJF signs distribution agreement for antibody to evaluate prostate cancer
11. 2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... the first time support an aid project with the donation of cochlear implants. ... the gift of hearing and thus a fair chance of leading an independent ...
(Date:1/18/2017)... Hills, CA (PRWEB) , ... January 18, 2017 ... ... of dental problems ranging from gum disease to enamel erosion, and those dental ... the Massachusetts Department of Public Health, many pregnant women are failing to get ...
(Date:1/17/2017)... ... January 17, 2017 , ... January is National Stalking Awareness Month (NSAM), ... lurk in the corners and commit the crime of stalking, a very real danger to ... an often overlooked factor in stalking and other crimes. , “Stalking: know it. Name it. ...
(Date:1/17/2017)... New York, NY (PRWEB) , ... January 17, 2017 , ... ... the grand opening of a new showroom at South Dixie Hwy in Miami, FL. ... Marketing Officer at Gym Source. “The new innovative in-store concept is designed to give ...
(Date:1/17/2017)... Chicago, Illinois (PRWEB) , ... January 17, 2017 , ... ... Antonio Breast Cancer Symposium (SABCS) or those who desire a more intimate review and ... Antonio: Breast Cancer – Bench to Bedside—is being offered by Imedex on February 4, ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... DUBLIN , Jan 18, 2017 Research ... Nausea and Vomiting Drugs Market 2017-2021" report to their offering. ... The global ... the period 2017-2021. Global Thoracic Surgery Market 2017-2021, ... from industry experts. The report covers the market landscape and its ...
(Date:1/18/2017)... Jan. 18, 2017 In China ... is where the Upgrade of China,s ... 13th Five-Year Plan for Economic and Social Development of ... Five-Year Plan), and the state council of the ... national strategic emerging industry development plan, identifying medical devices as ...
(Date:1/18/2017)... , January 18, 2017 Ximbio, a ... share research resources, has opened its first North American headquarters ... ... an expansion for Ximbio following its launch in October 2014 ... Technology (CRT), the commercialization arm of the foundation Cancer Research ...
Breaking Medicine Technology: